Laurus Labs
+33.44% revenue YoY
Q2 FY2027 · Period ended 30 Sep 2026
Basis: Consolidated, unaudited
Reported revenue (₹ crore, except EPS in ₹/share): 2,206.37
Read summary and comparison caveats
Laurus Labs reported consolidated revenue of ₹2,206.37 crore, up 33.44% year on year and 8.89% from June. Profit attributable to equity holders rose to ₹441.48 crore, compared with ₹194.97 crore a year ago and ₹367.60 crore in June. Total group profit after the share of associates and joint venture was ₹436.19 crore, a different attribution basis.
- Source: consolidated statement on PDF page 2 and notes on page 5. The statement is already in ₹ crore; no million/lakh conversion is applied. Changes use original amounts before rounding. EPS is reported and not annualised.
- Year ago is the quarter ended 30 Sep 2025; previous quarter is 30 Jun 2026. Equity holders' PAT of ₹441.48 crore plus non-controlling loss of ₹5.29 crore equals total group PAT of ₹436.19 crore. That total includes ₹0.55 crore share of associate/joint-venture losses; the preceding ₹436.74 crore PAT line is not substituted for owners' profit.
- Total tax expense was ₹155.08 crore versus ₹75.98 crore a year ago and ₹119.37 crore in June. Deferred-tax credits were ₹7.86 crore, ₹11.93 crore and ₹15.51 crore respectively. Reported PAT is not an adjusted or recurring-profit estimate.
- The group reports one pharmaceuticals segment. Consolidation includes Laurus Bio at 78.34%, associates and the 49% KRKA Pharma joint venture; standalone results are not mixed into the comparison.
- The proposed Synthesis/Sriam scheme remains subject to approvals. The company says these consolidated results do not give effect to the proposed merger. Laurus Generics GmbH liquidation remains ongoing through its statutory creditor-objection period; the note describes its net assets and results as not material.
- The company allotted 455,636 ESOP shares during the half year. Reported EPS uses its applicable share basis. The ₹1 per-share interim dividend approved on 29 Oct is a distribution decision, not an addition to quarterly PAT.
- No separate exceptional-item line appears in this consolidated statement. No EBITDA or acquisition-adjusted profit is inferred from a press release. Board-outcome, presentation and press-release notices are not counted as separate company results.
- Selected original-source coverage, not a complete market list. Raw RSS notice time has no timezone suffix.
Checked 29 Oct 2026
Open original filing